![]() ![]() A preliminary prospectus supplement related to the public offering has been filed with the SEC and is available on the SEC’s website located at. The shares of common stock being offered by HTG in the public offering as described above are being offered pursuant to a shelf registration statement filed by HTG with the Securities and Exchange Commission (SEC) that was declared effective on February 11, 2019. is acting as the sole book-running manager for the public offering. HTG anticipates using the net proceeds from the public offering for working capital and general corporate purposes, which may include capital expenditures and research and development, sales and marketing and general and administrative expenses.Ĭantor Fitzgerald & Co. The public offering of common stock and concurrent private placement of pre-funded warrants are expected to close on September 24, 2019, subject to customary closing conditions. ![]() The gross proceeds from the private placement are expected to be approximately $3.5 million, before deducting fees and offering expenses. Each pre-funded warrant will be immediately exercisable upon issuance, subject to beneficial ownership limitations, and will have an exercise price of $0.01 per share. Concurrently with the pricing of the underwritten public offering, HTG entered into a securities purchase agreement with certain institutional accredited investors for the sale of 5,411,687 pre-funded warrants exercisable for an aggregate of 5,411,687 shares of common stock, at a purchase price of $0.64 per pre-funded warrant. In addition, HTG has granted the underwriter for the public offering a 30-day option to purchase up to 3,821,548 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. ![]() The gross proceeds from the public offering are expected to be approximately $16.6 million, before deducting the underwriting discounts and commissions and offering expenses. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced the pricing of an underwritten public offering of 25,476,989 shares of its common stock at a price to the public of $0.65 per share. The HTG Molecular (HTGM) stock price soared 181.48% to trade at $152, rising from Friday’s closing price of $0.54.TUCSON, Ariz.-( BUSINESS WIRE)-HTG Molecular Diagnostics, Inc. However, I wouldn’t buy the shares after the recent parabolic rally, typically followed by a significant pullback. HTGM shares remain quite popular among investors as over 19 million had changed hands at writing and the buying momentum was still robust. The company plans to present data from the above process tomorrow, including the outcomes. HTG revealed that it was applying RNA profiling within its transcriptome-informed drug discovery process and had discovered differential regulation of the ferroptosis pathway by structurally similar compounds that target mTOR. Investors are looking forward to Dr Spitale’s presentation, which is bound to have a lot of new information regarding the use of RNA profiling in drug discovery. The company will be represented by key opinion leader (KOL) Dr Robert Spitale, PhD, from the University of California – Irvine. Most people expect the company to present breakthrough results backed by its innovative processes, which explains the two-day rally, which is likely to persist until tomorrow after the presentation. HTG will also present results from applying its transcriptome-informed drug discovery process. So, the question is, why did investors react so positively to this announcement? The simple answer is that apart from discussing the use of RNA profiling in the drug discovery process to understand mechanisms of action better and refine drug screening. The bullish momentum continued into the premarket trading session today, where the stock surged over 200% before retracing some of its gains. The announcement on Friday triggered a 117.57% rally in HTGM stock as investors eagerly anticipated the event. 800+ tradable assets are available for CFD trading in forex, shares, indices, commodities and cryptocurrencies. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |